Evidence map›Paper›PMID 27329124›Full record

ArticleInternational journal of hematology2016

Characterization of patients with aggressive adult T-cell leukemia-lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort.

Yukiko Nishi, Takuya Fukushima, Shogo Nomura, Takeaki Tomoyose, Sawako Nakachi, Kazuho Morichika, Iori Tedokon, Keita Tamaki, Natsuki Shimabukuro, Naoya Taira and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.Clinical medicine insights. Blood disorders · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Yukiko NishiDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Takuya FukushimaLaboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan. fukutaku@med.u-ryukyu.ac.jp.
Shogo NomuraBiostatistics Division, Center for Research and Administration and Support, National Cancer Center, Tokyo, Japan.
Takeaki TomoyoseDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Sawako NakachiDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Kazuho MorichikaDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Iori TedokonDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Keita TamakiDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Natsuki ShimabukuroDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Naoya TairaDepartment of Hematology, Heartlife Hospital, Nakagusuku, Japan.
Takashi MiyagiDepartment of Hematology, Heartlife Hospital, Nakagusuku, Japan.
Kaori KarimataDepartment of Hematology, Heartlife Hospital, Nakagusuku, Japan.
Masayo OhamaDepartment of Hematology, Heartlife Hospital, Nakagusuku, Japan.
Atsushi YamanohaDepartment of Hematology, Heartlife Hospital, Nakagusuku, Japan.
Kazumitsu TamakiDepartment of Hematology, Okinawa Prefectural Chubu Hospital, Uruma, Japan.
Masaki HayashiDepartment of Hematology, Nakagami Hospital, Okinawa, Japan.
Hitoshi ArakakiDepartment of Hematology, Naha City Hospital, Naha, Japan.
Jun-Nosuke UchiharaDepartment of Hematology, Naha City Hospital, Naha, Japan.
Kazuiku OhshiroDepartment of Hematology, Okinawa Prefectural Nambu Medical Center and Children's Medical Center, Haebaru, Japan.
Yoshitaka AsakuraDepartment of Hematology, Okinawa Red Cross Hospital, Naha, Japan.
Megumi Kuba-MiyaraLaboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan.
Kennosuke KarubeDepartment of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Hiroaki MasuzakiDivision of Endocrinology, Diabetes and Metabolism, Hematology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
University of the Ryukyus · JPHeart Life Hospital · JPNaha City Hospital · JPGunma Children's Medical Center · JPOkinawa Prefectural Chubu Hospital · JPOkinawa Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Okinawa Prefecture, located in the subtropics, is an area of endemic adult T-cell leukemia-lymphoma (ATL) in Japan. We retrospectively analyzed 659 patients with aggressive ATL in seven institutions in Okinawa between 2002 and 2011. The median patient age was 68 years. More patients were aged ≥90 years (2.6 %), in this study, than in a nationwide survey (<1 %). The median survival time (MST) of the entire cohort was 6.5 months. Of the 217 patients who had a clinical status similar to that stated in the eligibility criteria of JCOG9801 (a randomized phase III study comparing VCAP-AMP-VECP with CHOP-14), 147 who received the CHOP regimen had a poorer MST than those in the CHOP-14 arm of JCOG9801 (8 vs 11 months). The prevalence of strongyloidiasis in the ATL patients was much higher (12.4 %) than in the historical cohort who visited the University of the Ryukyus Hospital (3.4 %). Furthermore, strongyloidiasis may be associated with ATL-related deaths. These findings suggest that, compared with other areas in Japan, in Okinawa, the proportion of patients aged ≥90 years with clinical features of aggressive ATL is higher, outcomes are poorer, and the disease is associated with a higher prevalence of strongyloidiasis.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesCyclophosphamideDoxorubicinHumansJapanLeukemia-Lymphoma, Adult T-CellPrednisoneRetrospective StudiesStrongyloidiasisVincristineCyclophosphamideDoxorubicinPrednisoneVincristineAdult T-cell leukemia–lymphomaOkinawaRetrospective analysisStrongyloidiasisSubtropics

Identifiers

PMID27329124
OpenAlexW2475259087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.